Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling

被引:19
|
作者
Zhang, Haiyu [1 ]
Ge, Tingting [2 ]
Cui, Xiaoming [1 ]
Hou, Yan [1 ]
Ke, Chaofu [1 ]
Yang, Meng [2 ]
Yang, Kai [1 ]
Wang, Jingtao [1 ]
Guo, Bing [1 ]
Zhang, Fan [1 ]
Lou, Ge [2 ]
Li, Kang [1 ]
机构
[1] Harbin Med Univ, Dept Epidemiol & Biostat, Harbin 150081, Peoples R China
[2] Harbin Med Univ, Dept Gynecol Oncol, Tumor Hosp, Harbin 150086, Peoples R China
基金
中国国家自然科学基金; 高等学校博士学科点专项科研基金;
关键词
CHROMATOGRAPHY-MASS-SPECTROMETRY; T-CELL PROLIFERATION; INDOLEAMINE 2,3-DIOXYGENASE; POTENTIAL BIOMARKERS; DENDRITIC CELLS; STAGE-III; TRYPTOPHAN; IDENTIFICATION; INHIBITION; LYSOPHOSPHATIDYLCHOLINE;
D O I
10.1039/c4mb00407h
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epithelial ovarian cancer (EOC) is the most lethal of gynecologic malignancies due to the high rate of recurrence and poor prognosis. Predicting the prognosis in patients with EOC is clinically challenging, partly because appropriate biomarkers of recurrence have yet to be explored. In this prospective study, pre-treatment plasma samples were collected from 38 patients with stage III or IV EOC who were subsequently followed up. Ultra-performance liquid chromatography mass spectrometry was used to perform metabolic profiling, which yielded five metabolites that were potential biomarkers for EOC recurrence: L-tryptophan, kynurenine, bilirubin, LysoPC (14 : 0) and LysoPE (18 : 2). A combination of these five potential biomarkers strongly predicted recurrence, the area under the curve being 0.91. In summary, the candidate biomarkers identified in this study may both facilitate clinical prediction of EOC recurrence and prognosis and serve as potential therapeutic targets in patients with EOC.
引用
收藏
页码:516 / 521
页数:6
相关论文
共 50 条
  • [21] Plasma metabolic profiling analysis of nephrotoxicity induced by acyclovir using metabonomics coupled with multivariate data analysis
    Zhang, Xiuxiu
    Li, Yubo
    Zhou, Huifang
    Fan, Simiao
    Zhang, Zhenzhu
    Wang, Lei
    Zhang, Yanjun
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 97 : 151 - 156
  • [22] Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry
    Kim, Nam Ah
    Jin, Jing Hui
    Kim, Kyung-Hee
    Lim, Dae Gon
    Cheong, Heesun
    Kim, Yun Hwan
    Ju, Woong
    Kim, Seung Cheol
    Jeong, Seong Hoon
    ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (05) : 668 - 676
  • [23] Initial surgical management of advanced epithelial ovarian cancer
    Benjamin, I
    Rubin, SC
    CANCER INVESTIGATION, 1997, 15 (03) : 270 - 276
  • [24] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    Bryant, Andrew
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (01):
  • [25] Interval debulking surgery for advanced epithelial ovarian cancer
    Tangjitgamol, Siriwan
    Manusirivithaya, Sumonmal
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    Bryant, Andrew
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (04):
  • [26] Achievements and unmet needs in the management of advanced ovarian cancer
    Guarneri, Valentina
    Piacentini, Federico
    Barbieri, Elena
    Conte, Pier Franco
    GYNECOLOGIC ONCOLOGY, 2010, 117 (02) : 152 - 158
  • [27] Cytoreductive Surgery for Advanced Ovarian Cancer: Quo Vadis?
    Schorge, John O.
    Garrett, Leslie A.
    Goodman, Annekathryn
    ONCOLOGY-NEW YORK, 2011, 25 (10): : 928 - 934
  • [28] First line chemotherapy of advanced epithelial ovarian cancer
    Lhomme, C.
    Even, C.
    Morice, P.
    Balleyguier, C.
    Petrella, M. C.
    Gouy, S.
    Uzan, C.
    Duvillard, P.
    Pautier, P.
    BULLETIN DU CANCER, 2009, 96 (12) : 1207 - 1213
  • [29] Characterization of rare histological subtypes of ovarian cancer based on molecular profiling
    Takahashi, Nobutaka
    Hatakeyama, Keiichi
    Nagashima, Takeshi
    Ohshima, Keiichi
    Urakami, Kenichi
    Yamaguchi, Ken
    Hirashima, Yasuyuki
    CANCER MEDICINE, 2023, 12 (01): : 387 - 395
  • [30] Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer
    Cao, Lin-Lin
    Han, Yi
    Wang, Yuanxiao
    Pei, Lin
    Yue, Zhihong
    Qin, Li
    Liu, Boyu
    Cui, Jingwen
    Jia, Mei
    Wang, Hui
    FRONTIERS IN ENDOCRINOLOGY, 2022, 12